Trade Morphosys AG - MOR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.28 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02141% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.000812% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Germany | ||||||||
| Commission on trade | 0% |
| Prev. Close | 67.71 |
| Open | 67.66 |
| 1-Year Change | 129.28% |
| Day's Range | 67.66 - 67.76 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | 67.66 | 0.00 | 0.00% | 67.66 | 67.71 | 67.66 |
| Jul 24, 2024 | 67.66 | 0.00 | 0.00% | 67.66 | 67.66 | 67.66 |
| Jul 23, 2024 | 67.66 | 0.05 | 0.07% | 67.61 | 67.71 | 67.61 |
| Jul 22, 2024 | 67.66 | 0.05 | 0.07% | 67.61 | 67.66 | 67.61 |
| Jul 19, 2024 | 67.56 | 0.65 | 0.97% | 66.91 | 67.66 | 66.91 |
| Jul 18, 2024 | 67.56 | 0.00 | 0.00% | 67.56 | 67.66 | 67.56 |
| Jul 17, 2024 | 67.66 | 0.10 | 0.15% | 67.56 | 67.66 | 67.56 |
| Jul 16, 2024 | 67.66 | 0.05 | 0.07% | 67.61 | 67.66 | 67.61 |
| Jul 15, 2024 | 67.66 | 0.00 | 0.00% | 67.66 | 67.71 | 67.66 |
| Jul 12, 2024 | 67.61 | 0.05 | 0.07% | 67.56 | 67.76 | 67.56 |
| Jul 11, 2024 | 67.56 | 0.05 | 0.07% | 67.51 | 67.61 | 67.51 |
| Jul 10, 2024 | 67.61 | 0.10 | 0.15% | 67.51 | 67.66 | 67.46 |
| Jul 9, 2024 | 67.96 | 0.45 | 0.67% | 67.51 | 67.96 | 67.51 |
| Jul 8, 2024 | 67.56 | 0.05 | 0.07% | 67.51 | 67.61 | 67.51 |
| Jul 5, 2024 | 67.51 | 0.00 | 0.00% | 67.51 | 67.66 | 67.51 |
| Jul 4, 2024 | 67.56 | 0.65 | 0.97% | 66.91 | 67.61 | 66.91 |
| Jul 3, 2024 | 66.91 | 0.10 | 0.15% | 66.81 | 67.51 | 66.81 |
| Jul 2, 2024 | 67.56 | 0.05 | 0.07% | 67.51 | 67.61 | 66.91 |
| Jul 1, 2024 | 67.56 | 0.15 | 0.22% | 67.41 | 67.56 | 67.41 |
| Jun 28, 2024 | 67.51 | 0.60 | 0.90% | 66.91 | 67.56 | 66.91 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Morphosys Company profile
About MorphoSys AG
MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, MorphoSys AG revenues decreased 45% to EUR179.6M. Net loss totaled EUR514.5M vs. income of EUR97.9M. Revenues reflect USA and Canada segment decrease of 51% to EUR156.3M. Net loss reflects Impairment - Goodwill increase from EUR2.1M to EUR230.7M (expense), Other R&D increase of 80% to EUR153.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR3.01 to -EUR15.40.
Equity composition
12/2008, 3-for-1 stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
Semmelweisstr. 7
PLANEGG
BAYERN 82152
DE
News
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com